Outcome of the Board meeting held on 19.05.2026
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ZIM Laboratories Limited Board approved audited standalone and consolidated financial results for FY2026 (year ended 31 March 2026). Consolidated revenue stood at Rs. 37,440 lakhs with PAT of Rs. 583.81 lakhs, compared to Rs. 37,903 lakhs revenue and Rs. 1,216.50 lakhs PAT in FY2025 - a significant ~52% decline in profitability. Q4 standalone PAT was Rs. 328.21 lakhs. Deloitte Haskins & Sells LLP issued an unmodified (clean) audit opinion with no qualifications. The Board also appointed M/s Dhananjay V. Joshi & Associates as Cost Auditor for FY 2026-27. Cash position improved substantially to Rs. 2,512.19 lakhs from Rs. 194.66 lakhs previously.
Profitability declined sharply year-over-year despite stable revenues, which may concern investors. However, the clean audit opinion and strong cash position provide some comfort. The stock may face near-term pressure due to the earnings decline.